Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion-Reference-Cited by-同舟云学术

Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion

Published:2006-04 Issue:3 Volume:17 Page:165-171
ISSN:0957-5235
Container-title:Blood Coagulation & Fibrinolysis
language:en
Short-container-title:

Author:

Fernandez Maximilian,Yu Tabitha,Bjornson Erik,Luu Huong,Spotts Gerald

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology,General Medicine

Reference34 articles.

1. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray;Blood,1994

2. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia. The Recombinate Previously Treated Patient Study Group;White;Thromb Haemost,1997

3. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients;Courter;Semin Hematol,2001

4. ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A;Lusher;Haemophilia,2003

5. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients [abstract];Rothschild;Haemophilia,2002

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro;TH Open;2020-10

2. Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries;Haemophilia;2018-11-05

3. Continuous infusion of coagulation factor concentrates during intensive treatment;Haemophilia;2017-09-05

4. Continuous Infusion of Coagulation Products in Hemophilia;Textbook of Hemophilia;2014-04-24

5. Progress ofin vitrofactor VIII coagulant activity from 0 to 8 hours after reconstitution;Blood Research;2014